CDL 200
Alternative Names: CDL200Latest Information Update: 28 Jul 2024
At a glance
- Originator iNtRON Biotechnology
- Class Antibacterials; Endolysins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Clostridium infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Clostridium-infections in South Korea (PO, Capsule)
- 13 Jul 2022 CDL 200 is still in preclinical development for Clostridium-infections in South Korea
- 11 Jul 2022 Preclinical trials in Clostridium infections in Europe (PO)